Toxicity of asciminib in real clinical practice: Analysis of side effects and cross-toxicity with tyrosine kinase inhibitors

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Pérez-Lamas, Lucía
• dc.contributor.author Vélez, Patricia
• dc.contributor.author García-Gutiérrez, Valentín
• dc.date.accessioned 2024-04-30T06:12:35Z
• dc.date.available 2024-04-30T06:12:35Z
• dc.date.issued 2023
• dc.description.abstract (1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intolerant patients, as it is a first-in-class inhibitor with a more selective mechanism of action different from the ATP-competitive inhibition that occurs with TKIs. Therefore, our goal was to analyze toxicities shown with asciminib as well as to study cross-toxicity with previous TKIs. (2) Methods: An observational, multicenter, retrospective study was performed with data from 77 patients with CML with therapeutic failure to second-generation TKIs who received asciminib through a managed-access program (MAP) (3) Results: With a median follow-up of 13.7 months, 22 patients (28.5%) discontinued treatment: 32% (7/22) due to intolerance and 45% (10/22) due to resistance. Fifty-five percent of the patients reported adverse effects (AEs) with asciminib and eighteen percent grade 3-4. Most frequent AEs were: fatigue (18%), thrombocytopenia (17%), anemia (12%), and arthralgias (12%). None of the patients experienced cardiovascular events or occlusive arterial disease. Further, 26%, 25%, and 9% of patients required dose adjustment, temporary suspension, or definitive discontinuation of treatment, respectively. Toxicities under asciminib seemed lower than with prior TKIs for anemia, cardiovascular events, pleural/pericardial effusion, diarrhea, and edema. Cross-toxicity risk was statistically significant for thrombocytopenia, anemia, neutropenia, fatigue, vomiting, and pancreatitis. (4) Conclusion: Asciminib is a molecule with a good safety profile and with a low rate of AEs. However, despite its new mechanism of action, asciminib presents a risk of cross-toxicity with classical TKIs for some AEs.
• dc.format.mimetype application/pdf
• dc.identifier.citation Pérez-Lamas L, Luna A, Boque C, Xicoy B, Giraldo P, Pérez López R, et al. Toxicity of asciminib in real clinical practice: Analysis of side effects and cross-toxicity with tyrosine kinase inhibitors. Cancers (Basel). 2023 Feb 7;15(4):1045. DOI: 10.3390/cancers15041045
• dc.identifier.doi http://dx.doi.org/10.3390/cancers15041045
• dc.identifier.issn 2072-6694
• dc.identifier.uri http://hdl.handle.net/10230/59947
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Cancers (Basel). 2023 Feb 7;15(4):1045
• dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Asciminib
• dc.subject.keyword Chronic myeloid leukemia
• dc.subject.keyword Drug intolerance
• dc.subject.keyword Toxicities
• dc.title Toxicity of asciminib in real clinical practice: Analysis of side effects and cross-toxicity with tyrosine kinase inhibitors
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion